Researchers published a Nature Biotechnology report describing envelope-engineered virus‑like particles (VLPs) capable of delivering gene‑editing cargo to human hematopoietic stem and progenitor cells (HSPCs) in vivo. The platform achieved targeted editing without ex vivo harvest, offering a potential route to simplify curative therapies for blood disorders. The work demonstrated editing in preclinical models and detailed the engineering behind the VLP envelopes that enable cell‑specific uptake. The study positions VLP-mediated delivery as a contender to viral-vector and nanoparticle approaches for in vivo gene correction. If translated clinically, envelope‑engineered VLPs could reduce manufacturing complexity and costs associated with autologous HSPC therapies, accelerating development timelines for genetic blood diseases.